<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="8" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font6" size="8" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font7" size="8" family="GillSans" color="#000000"/>
<text top="41" left="55" width="174" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title"><i>Cost Effectiveness and Resource Allocation</i></text>
<text top="41" left="229" width="28" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="0" tag_type="title"> 2006, </text>
<text top="41" left="257" width="5" height="10" font="font2" id="p1_t3" reading_order_no="2" segment_no="0" tag_type="title"><b>4</b></text>
<text top="41" left="262" width="12" height="10" font="font1" id="p1_t4" reading_order_no="3" segment_no="0" tag_type="title">:17</text>
<text top="41" left="355" width="199" height="10" font="font1" id="p1_t5" reading_order_no="4" segment_no="1" tag_type="text">http://www.resource-allocation.com/content/4/1/17</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t6" reading_order_no="141" segment_no="9" tag_type="text">Page 4 of 8</text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t7" reading_order_no="142" segment_no="10" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="93" segment_no="5" tag_type="text">Specific rates of health care utilization during the six</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="94" segment_no="5" tag_type="text">months prior to the index date (i.e., prior to identification</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="95" segment_no="5" tag_type="text">of these patients having anemia) were greater for patients</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="96" segment_no="5" tag_type="text">with co-morbid anemia (Table <a href="">2</a>). During the six-month</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="97" segment_no="5" tag_type="text">baseline period, anemic persons had significantly more</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="98" segment_no="5" tag_type="text">claims for hospitalizations, ICU care, and episodes of</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="99" segment_no="5" tag_type="text">acute exacerbations of COPD (AECB) and pneumonia.</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="100" segment_no="5" tag_type="text">For example, being classified with co-morbid anemia was</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="101" segment_no="5" tag_type="text">associated with a greater need for ICU care (15.5 claims</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="102" segment_no="5" tag_type="text">per 100 patients with anemia during the baseline period</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="103" segment_no="5" tag_type="text">vs. 7.3 claims per 100 patients without anemia, p &lt;</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="104" segment_no="5" tag_type="text">0.001). These differences indicate greater baseline severity</text>
<text top="580" left="55" width="212" height="9" font="font4" id="p1_t20" reading_order_no="105" segment_no="5" tag_type="text">of illness among patients with COPD and anemia.</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="106" segment_no="8" tag_type="text">Ta<a href="">ble 3 present</a>s the unadjusted total claims (charges) and</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="107" segment_no="8" tag_type="text">reimbursements (payments) after the index date (in 2004</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="108" segment_no="8" tag_type="text">dollars). Average annual payments from Medicare were</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="109" segment_no="8" tag_type="text">substantially higher among those with anemia. Medicare</text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="110" segment_no="8" tag_type="text">spent $1,466 per patient per year among COPD patients</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="111" segment_no="8" tag_type="text">with anemia vs. $649 per patient per year in non-anemic</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="112" segment_no="8" tag_type="text">COPD patients (p &lt; 0.001). Resource utilization rates</text>
<text top="686" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="113" segment_no="8" tag_type="text">among patients with anemia (Table<a href=""> 4.)</a>, as well as pay-</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="114" segment_no="8" tag_type="text">ments for COPD patients with anemia were higher in</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="115" segment_no="8" tag_type="text">every resource utilization category (Figur<a href="">e 2). Rates of</a></text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="116" segment_no="8" tag_type="text">mechanical ventilation, ICU care, emergency department</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t32" reading_order_no="117" segment_no="6" tag_type="text">visits, and other resource use were also higher among</text>
<text top="451" left="313" width="208" height="9" font="font4" id="p1_t33" reading_order_no="118" segment_no="6" tag_type="text">COPD patients diagnosed with anem<a href="">ia (Table 4).</a></text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t34" reading_order_no="119" segment_no="7" tag_type="text">Costs for Medicare enrollees in both groups, with and</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t35" reading_order_no="120" segment_no="7" tag_type="text">without anemia, rose after the index date. The increase in</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t36" reading_order_no="121" segment_no="7" tag_type="text">claims was 78.1% for COPD patients with anemia and</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t37" reading_order_no="122" segment_no="7" tag_type="text">50.9% for patients without anemia (p &lt; 0.001); the</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t38" reading_order_no="123" segment_no="7" tag_type="text">increase in payments was 71.5% for patients with anemia</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t39" reading_order_no="124" segment_no="7" tag_type="text">and 48.5% among patients without anemia (p &lt; 0.001).</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t40" reading_order_no="125" segment_no="7" tag_type="text">Using linear regression to control for baseline differences</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t41" reading_order_no="126" segment_no="7" tag_type="text">in severity of illness (e.g., number of co-morbid illnesses,</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t42" reading_order_no="127" segment_no="7" tag_type="text">need for ventilation support, and episodes of pneumonia</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t43" reading_order_no="128" segment_no="7" tag_type="text">and acute exacerbations of chronic bronchitis in the six</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t44" reading_order_no="129" segment_no="7" tag_type="text">months prior to the index date) and preceding health care</text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t45" reading_order_no="130" segment_no="7" tag_type="text">use (e.g., frequency of hospital admissions and emergency</text>
<text top="615" left="313" width="241" height="9" font="font4" id="p1_t46" reading_order_no="131" segment_no="7" tag_type="text">room care for COPD) the incremental independent</text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t47" reading_order_no="132" segment_no="7" tag_type="text">annual per patient charges and reimbursements associ-</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t48" reading_order_no="133" segment_no="7" tag_type="text">ated with anemia among COPD patients were calculated</text>
<text top="651" left="313" width="241" height="9" font="font4" id="p1_t49" reading_order_no="134" segment_no="7" tag_type="text">to be $8,811 (p &lt; 0.001, 95% CI: $8,136 to $9,487) for</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t50" reading_order_no="135" segment_no="7" tag_type="text">charges and $3,582 (p &lt; 0.001, 95% CI: $3,299 to $3,865)</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t51" reading_order_no="136" segment_no="7" tag_type="text">for payments. The independent contribution of anemia to</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t52" reading_order_no="137" segment_no="7" tag_type="text">costs in COPD was present in all categories of resource uti-</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t53" reading_order_no="138" segment_no="7" tag_type="text">lization (Figure <a href="">3). O</a>f note, anemia care (defined as med-</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t54" reading_order_no="139" segment_no="7" tag_type="text">ical claims with an anemia diagnosis) did not appear to</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t55" reading_order_no="140" segment_no="7" tag_type="text">account directly for these incremental differences in cost.</text>
<text top="87" left="55" width="152" height="7" font="font5" id="p1_t56" reading_order_no="5" segment_no="2" tag_type="title"><b>Table 1: Baseline Patient Characteristics</b></text>
<text top="105" left="101" width="32" height="7" font="font5" id="p1_t57" reading_order_no="6" segment_no="3" tag_type="table"><b>Variable</b></text>
<text top="105" left="204" width="77" height="7" font="font5" id="p1_t58" reading_order_no="7" segment_no="3" tag_type="table"><b>COPD with Anemia</b></text>
<text top="114" left="219" width="46" height="7" font="font5" id="p1_t59" reading_order_no="8" segment_no="3" tag_type="table"><b>(n = 27,932)</b></text>
<text top="105" left="329" width="75" height="7" font="font5" id="p1_t60" reading_order_no="9" segment_no="3" tag_type="table"><b>Non-anemic COPD</b></text>
<text top="114" left="342" width="50" height="7" font="font5" id="p1_t61" reading_order_no="10" segment_no="3" tag_type="table"><b>(n = 104,492)</b></text>
<text top="105" left="478" width="28" height="7" font="font5" id="p1_t62" reading_order_no="11" segment_no="3" tag_type="table"><b>P value</b></text>
<text top="136" left="59" width="52" height="7" font="font6" id="p1_t63" reading_order_no="12" segment_no="3" tag_type="table"><i><b>Demographics</b></i></text>
<text top="147" left="59" width="74" height="7" font="font7" id="p1_t64" reading_order_no="13" segment_no="3" tag_type="table">Age, mean (SD), years</text>
<text top="147" left="225" width="34" height="7" font="font7" id="p1_t65" reading_order_no="14" segment_no="3" tag_type="table">77.5 ± 7.8</text>
<text top="147" left="350" width="34" height="7" font="font7" id="p1_t66" reading_order_no="15" segment_no="3" tag_type="table">74.7 ± 7.6</text>
<text top="147" left="480" width="23" height="7" font="font7" id="p1_t67" reading_order_no="16" segment_no="3" tag_type="table">&lt;0.001</text>
<text top="157" left="59" width="89" height="7" font="font7" id="p1_t68" reading_order_no="17" segment_no="3" tag_type="table">Age distribution (years, %)</text>
<text top="167" left="69" width="21" height="7" font="font7" id="p1_t69" reading_order_no="18" segment_no="3" tag_type="table">65–69</text>
<text top="167" left="232" width="20" height="7" font="font7" id="p1_t70" reading_order_no="19" segment_no="3" tag_type="table">19.0%</text>
<text top="167" left="357" width="20" height="7" font="font7" id="p1_t71" reading_order_no="20" segment_no="3" tag_type="table">31.5%</text>
<text top="167" left="480" width="23" height="7" font="font7" id="p1_t72" reading_order_no="21" segment_no="3" tag_type="table">&lt;0.001</text>
<text top="177" left="69" width="21" height="7" font="font7" id="p1_t73" reading_order_no="22" segment_no="3" tag_type="table">70–74</text>
<text top="177" left="232" width="20" height="7" font="font7" id="p1_t74" reading_order_no="23" segment_no="3" tag_type="table">20.1%</text>
<text top="177" left="357" width="20" height="7" font="font7" id="p1_t75" reading_order_no="24" segment_no="3" tag_type="table">23.0%</text>
<text top="188" left="69" width="21" height="7" font="font7" id="p1_t76" reading_order_no="25" segment_no="3" tag_type="table">75–79</text>
<text top="188" left="232" width="20" height="7" font="font7" id="p1_t77" reading_order_no="26" segment_no="3" tag_type="table">21.4%</text>
<text top="188" left="357" width="20" height="7" font="font7" id="p1_t78" reading_order_no="27" segment_no="3" tag_type="table">18.7%</text>
<text top="198" left="69" width="21" height="7" font="font7" id="p1_t79" reading_order_no="28" segment_no="3" tag_type="table">80–84</text>
<text top="198" left="232" width="20" height="7" font="font7" id="p1_t80" reading_order_no="29" segment_no="3" tag_type="table">18.7%</text>
<text top="198" left="357" width="20" height="7" font="font7" id="p1_t81" reading_order_no="30" segment_no="3" tag_type="table">13.7%</text>
<text top="208" left="69" width="15" height="7" font="font7" id="p1_t82" reading_order_no="31" segment_no="3" tag_type="table">&gt; 84</text>
<text top="208" left="232" width="20" height="7" font="font7" id="p1_t83" reading_order_no="32" segment_no="3" tag_type="table">20.6%</text>
<text top="208" left="357" width="20" height="7" font="font7" id="p1_t84" reading_order_no="33" segment_no="3" tag_type="table">12.1%</text>
<text top="218" left="59" width="29" height="7" font="font7" id="p1_t85" reading_order_no="34" segment_no="3" tag_type="table">Male (%)</text>
<text top="218" left="232" width="20" height="7" font="font7" id="p1_t86" reading_order_no="35" segment_no="3" tag_type="table">34.2%</text>
<text top="218" left="357" width="20" height="7" font="font7" id="p1_t87" reading_order_no="36" segment_no="3" tag_type="table">42.4%</text>
<text top="218" left="480" width="23" height="7" font="font7" id="p1_t88" reading_order_no="37" segment_no="3" tag_type="table">&lt;0.001</text>
<text top="229" left="59" width="285" height="7" font="font6" id="p1_t89" reading_order_no="38" segment_no="3" tag_type="table"><i><b>Pulmonary Characteristics of Interest Present in the Six Month Baseline Period</b></i></text>
<text top="239" left="59" width="102" height="7" font="font7" id="p1_t90" reading_order_no="39" segment_no="3" tag_type="table">Concomitant asthma diagnosis</text>
<text top="239" left="232" width="20" height="7" font="font7" id="p1_t91" reading_order_no="40" segment_no="3" tag_type="table">25.2%</text>
<text top="239" left="357" width="20" height="7" font="font7" id="p1_t92" reading_order_no="41" segment_no="3" tag_type="table">22.6%</text>
<text top="239" left="480" width="23" height="7" font="font7" id="p1_t93" reading_order_no="42" segment_no="3" tag_type="table">&lt;0.001</text>
<text top="249" left="59" width="94" height="7" font="font7" id="p1_t94" reading_order_no="43" segment_no="3" tag_type="table">Use of supplemental oxygen</text>
<text top="249" left="234" width="16" height="7" font="font7" id="p1_t95" reading_order_no="44" segment_no="3" tag_type="table">9.8%</text>
<text top="249" left="359" width="16" height="7" font="font7" id="p1_t96" reading_order_no="45" segment_no="3" tag_type="table">3.7%</text>
<text top="249" left="480" width="23" height="7" font="font7" id="p1_t97" reading_order_no="46" segment_no="3" tag_type="table">&lt;0.001</text>
<text top="259" left="59" width="325" height="7" font="font6" id="p1_t98" reading_order_no="47" segment_no="3" tag_type="table"><i><b>Comorbidities, % (by ICD-9 coded organ system) Present in the Six Month Baseline Period</b></i></text>
<text top="270" left="59" width="76" height="7" font="font7" id="p1_t99" reading_order_no="48" segment_no="3" tag_type="table">Infectious and parasitic</text>
<text top="270" left="234" width="16" height="7" font="font7" id="p1_t100" reading_order_no="49" segment_no="3" tag_type="table">1.7%</text>
<text top="270" left="359" width="16" height="7" font="font7" id="p1_t101" reading_order_no="50" segment_no="3" tag_type="table">1.4%</text>
<text top="270" left="480" width="23" height="7" font="font7" id="p1_t102" reading_order_no="51" segment_no="3" tag_type="table">&lt;0.001</text>
<text top="280" left="59" width="47" height="7" font="font7" id="p1_t103" reading_order_no="52" segment_no="3" tag_type="table">Skin disorders</text>
<text top="280" left="234" width="16" height="7" font="font7" id="p1_t104" reading_order_no="53" segment_no="3" tag_type="table">2.3%</text>
<text top="280" left="359" width="16" height="7" font="font7" id="p1_t105" reading_order_no="54" segment_no="3" tag_type="table">2.2%</text>
<text top="280" left="487" width="10" height="7" font="font7" id="p1_t106" reading_order_no="55" segment_no="3" tag_type="table">NS</text>
<text top="290" left="59" width="65" height="7" font="font7" id="p1_t107" reading_order_no="56" segment_no="3" tag_type="table">Digestive disorders</text>
<text top="290" left="234" width="16" height="7" font="font7" id="p1_t108" reading_order_no="57" segment_no="3" tag_type="table">2.5%</text>
<text top="290" left="359" width="16" height="7" font="font7" id="p1_t109" reading_order_no="58" segment_no="3" tag_type="table">2.5%</text>
<text top="290" left="487" width="10" height="7" font="font7" id="p1_t110" reading_order_no="59" segment_no="3" tag_type="table">NS</text>
<text top="300" left="59" width="56" height="7" font="font7" id="p1_t111" reading_order_no="60" segment_no="3" tag_type="table">Mental disorders</text>
<text top="300" left="234" width="16" height="7" font="font7" id="p1_t112" reading_order_no="61" segment_no="3" tag_type="table">3.3%</text>
<text top="300" left="359" width="16" height="7" font="font7" id="p1_t113" reading_order_no="62" segment_no="3" tag_type="table">2.9%</text>
<text top="300" left="480" width="23" height="7" font="font7" id="p1_t114" reading_order_no="63" segment_no="3" tag_type="table">&lt;0.001</text>
<text top="311" left="59" width="81" height="7" font="font7" id="p1_t115" reading_order_no="64" segment_no="3" tag_type="table">Genitourinary disorders</text>
<text top="311" left="234" width="16" height="7" font="font7" id="p1_t116" reading_order_no="65" segment_no="3" tag_type="table">3.9%</text>
<text top="311" left="359" width="16" height="7" font="font7" id="p1_t117" reading_order_no="66" segment_no="3" tag_type="table">3.3%</text>
<text top="311" left="480" width="23" height="7" font="font7" id="p1_t118" reading_order_no="67" segment_no="3" tag_type="table">&lt;0.001</text>
<text top="321" left="59" width="49" height="7" font="font7" id="p1_t119" reading_order_no="68" segment_no="3" tag_type="table">Blood diseases</text>
<text top="321" left="234" width="16" height="7" font="font7" id="p1_t120" reading_order_no="69" segment_no="3" tag_type="table">4.3%</text>
<text top="321" left="359" width="16" height="7" font="font7" id="p1_t121" reading_order_no="70" segment_no="3" tag_type="table">0.8%</text>
<text top="321" left="482" width="19" height="7" font="font7" id="p1_t122" reading_order_no="71" segment_no="3" tag_type="table">&lt;0.01</text>
<text top="331" left="59" width="54" height="7" font="font7" id="p1_t123" reading_order_no="72" segment_no="3" tag_type="table">Nervous system</text>
<text top="331" left="234" width="16" height="7" font="font7" id="p1_t124" reading_order_no="73" segment_no="3" tag_type="table">4.4%</text>
<text top="331" left="359" width="16" height="7" font="font7" id="p1_t125" reading_order_no="74" segment_no="3" tag_type="table">6.3%</text>
<text top="331" left="480" width="23" height="7" font="font7" id="p1_t126" reading_order_no="75" segment_no="3" tag_type="table">&lt;0.001</text>
<text top="341" left="59" width="87" height="7" font="font7" id="p1_t127" reading_order_no="76" segment_no="3" tag_type="table">Musculoskeletal disorders</text>
<text top="341" left="234" width="16" height="7" font="font7" id="p1_t128" reading_order_no="77" segment_no="3" tag_type="table">7.7%</text>
<text top="341" left="359" width="16" height="7" font="font7" id="p1_t129" reading_order_no="78" segment_no="3" tag_type="table">9.0%</text>
<text top="341" left="480" width="23" height="7" font="font7" id="p1_t130" reading_order_no="79" segment_no="3" tag_type="table">&lt;0.001</text>
<text top="352" left="59" width="94" height="7" font="font7" id="p1_t131" reading_order_no="80" segment_no="3" tag_type="table">Other respiratory disorders</text>
<text top="352" left="234" width="16" height="7" font="font7" id="p1_t132" reading_order_no="81" segment_no="3" tag_type="table">8.3%</text>
<text top="352" left="359" width="16" height="7" font="font7" id="p1_t133" reading_order_no="82" segment_no="3" tag_type="table">8.8%</text>
<text top="352" left="480" width="23" height="7" font="font7" id="p1_t134" reading_order_no="83" segment_no="3" tag_type="table">&lt;0.001</text>
<text top="362" left="59" width="83" height="7" font="font7" id="p1_t135" reading_order_no="84" segment_no="3" tag_type="table">Endocrine and metabolic</text>
<text top="362" left="234" width="16" height="7" font="font7" id="p1_t136" reading_order_no="85" segment_no="3" tag_type="table">8.5%</text>
<text top="362" left="359" width="16" height="7" font="font7" id="p1_t137" reading_order_no="86" segment_no="3" tag_type="table">7.9%</text>
<text top="362" left="480" width="23" height="7" font="font7" id="p1_t138" reading_order_no="87" segment_no="3" tag_type="table">&lt;0.001</text>
<text top="372" left="59" width="72" height="7" font="font7" id="p1_t139" reading_order_no="88" segment_no="3" tag_type="table">Circulatory disorders</text>
<text top="372" left="232" width="20" height="7" font="font7" id="p1_t140" reading_order_no="89" segment_no="3" tag_type="table">26.8%</text>
<text top="372" left="357" width="20" height="7" font="font7" id="p1_t141" reading_order_no="90" segment_no="3" tag_type="table">26.0%</text>
<text top="372" left="482" width="19" height="7" font="font7" id="p1_t142" reading_order_no="91" segment_no="3" tag_type="table">&lt;0.01</text>
<text top="394" left="59" width="282" height="7" font="font7" id="p1_t143" reading_order_no="92" segment_no="4" tag_type="text">Abbreviations: COPD – Chronic obstructive pulmonary disease, NS – not significant</text>
</page>
</pdf2xml>
